The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice
The article describes the peculiarities of drug provision for patients with psoriatic arthritis (PsA) in the Republic of Karelia. We present a clinical case of effective treatment with interleukin 17 inhibitor ixekizumab (IXE) in a randomized clinical trial and real clinical practice in a patient wi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1154 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023420527378432 |
|---|---|
| author | I. M. Marusenko O. N. Sakovich |
| author_facet | I. M. Marusenko O. N. Sakovich |
| author_sort | I. M. Marusenko |
| collection | DOAJ |
| description | The article describes the peculiarities of drug provision for patients with psoriatic arthritis (PsA) in the Republic of Karelia. We present a clinical case of effective treatment with interleukin 17 inhibitor ixekizumab (IXE) in a randomized clinical trial and real clinical practice in a patient with PsA. The distinctive feature of this case is the severity of PsA course that was not controlled by standard methods of therapy. IXE treatment was characterized by a rapid clinical improvement of both articular and skin symptoms and subsequent achievement of remission, which lasted for 3 years (on the therapy). The forced interruption of the treatment led to the relapse of the disease in a short amount of time. In 2 years IXE therapy was resumed; after 6 months of continuing treatment a stable remission of PsA was achieved. The patient is still in clinical remission (on therapy). |
| format | Article |
| id | doaj-art-b40a9ecaae8c4bb1aa763abd42e63332 |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2021-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-b40a9ecaae8c4bb1aa763abd42e633322025-08-20T03:01:22ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2021-06-01153869010.14412/1996-7012-2021-3-86-902368The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practiceI. M. Marusenko0O. N. Sakovich1Petrozavodsk State University, medical institute, department of hospital therapyV.A. Baranov republican hospitalThe article describes the peculiarities of drug provision for patients with psoriatic arthritis (PsA) in the Republic of Karelia. We present a clinical case of effective treatment with interleukin 17 inhibitor ixekizumab (IXE) in a randomized clinical trial and real clinical practice in a patient with PsA. The distinctive feature of this case is the severity of PsA course that was not controlled by standard methods of therapy. IXE treatment was characterized by a rapid clinical improvement of both articular and skin symptoms and subsequent achievement of remission, which lasted for 3 years (on the therapy). The forced interruption of the treatment led to the relapse of the disease in a short amount of time. In 2 years IXE therapy was resumed; after 6 months of continuing treatment a stable remission of PsA was achieved. The patient is still in clinical remission (on therapy).https://mrj.ima-press.net/mrj/article/view/1154psoriasispsoriatic arthritistherapymethotrexateixekizumab |
| spellingShingle | I. M. Marusenko O. N. Sakovich The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice Современная ревматология psoriasis psoriatic arthritis therapy methotrexate ixekizumab |
| title | The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice |
| title_full | The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice |
| title_fullStr | The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice |
| title_full_unstemmed | The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice |
| title_short | The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice |
| title_sort | efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis data from real clinical practice |
| topic | psoriasis psoriatic arthritis therapy methotrexate ixekizumab |
| url | https://mrj.ima-press.net/mrj/article/view/1154 |
| work_keys_str_mv | AT immarusenko theefficacyoftheinterleukin17inhibitorixekizumabinpsoriaticarthritisdatafromrealclinicalpractice AT onsakovich theefficacyoftheinterleukin17inhibitorixekizumabinpsoriaticarthritisdatafromrealclinicalpractice AT immarusenko efficacyoftheinterleukin17inhibitorixekizumabinpsoriaticarthritisdatafromrealclinicalpractice AT onsakovich efficacyoftheinterleukin17inhibitorixekizumabinpsoriaticarthritisdatafromrealclinicalpractice |